Inhibition of breast cancer growth with the combination of lapatinib and an ADAM protease inhibitor

被引：0
|
作者：
Witters, L. M.
Scherle, P. A.
Friedman, S. M.
Redman, J.
Fridman, J. S.
Caulder, E.
Lipton, A.
机构：
[1] Penn State Univ, Coll Med, Hershey, PA USA
[2] Incyte Corp, Wilmington, DE USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S82 / S82
页数：1
相关论文
共 50 条
  • [21] Selective Inhibition of HER2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir
    Shim, Joong Sup
    Rao, Rajini
    Beebe, Kristin
    Neckers, Len
    Han, Inkyu
    Nahta, Rita
    Liu, Jun O.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (20): : 1576 - 1590
  • [22] Lapatinib in metastatic breast cancer
    Frenel, J-S
    Bourbouloux, E.
    Berton-Rigaud, D.
    Sadot-Lebouvier, S.
    Zanetti, A.
    Campone, M.
    WOMENS HEALTH, 2009, 5 (06) : 603 - 612
  • [23] Synergistic inhibition of HER2 positive breast cancer by triptolide and lapatinib
    Chalugun, P.
    Shim, J. S.
    Korangath, P.
    Sukumar, S.
    Liu, J. O.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 36 - 36
  • [24] Synergistic inhibition of HER2 positive breast cancer by triptolide and lapatinib
    Chalugun, Paweena
    Shim, Joong Sup
    Korangath, Preethi C.
    Sukumar, Saraswati
    Liu, Jun O.
    CANCER RESEARCH, 2014, 74 (19)
  • [25] INHIBITION OF BREAST-CANCER CELL-GROWTH INVITRO BY A TYROSINE KINASE INHIBITOR
    REDDY, KB
    MANGOLD, GL
    TANDON, AK
    YONEDA, T
    MUNDY, GR
    ZILBERSTEIN, A
    OSBORNE, CK
    CANCER RESEARCH, 1992, 52 (13) : 3636 - 3641
  • [26] Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
    Hurvitz, Sara A.
    Kakkar, Reva
    BREAST CANCER-TARGETS AND THERAPY, 2012, 4 : 35 - 51
  • [27] Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines
    Vannini, Ivan
    Zoli, Wainer
    Fabbri, Francesco
    Ulivi, Paola
    Tesei, Anna
    Carloni, Silvia
    Brigliadori, Giovanni
    Amadori, Dino
    ANTI-CANCER DRUGS, 2009, 20 (10) : 918 - 925
  • [28] Synergistic Growth Inhibition with a PI3 Kinase/mTOR Inhibitor Plus Lapatinib.
    Speicher, T. J.
    Hackl, W.
    Lipton, A.
    CANCER RESEARCH, 2009, 69 (24) : 861S - 861S
  • [29] Lapatinib in combination with Taxanes (T) - tolerability data in 484 patients with breast cancer (BC)
    Burris, H.
    Crown, J. P.
    Jones, S.
    Oliva, C.
    Parikh, R. O. M. A.
    Stein, S.
    EJC SUPPLEMENTS, 2007, 5 (04): : 216 - 216
  • [30] Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer
    van der Noll, R.
    Smit, W. M.
    Wymenga, A. N. M.
    Boss, D. S.
    Grob, M.
    Huitema, A. D. R.
    Rosing, H.
    Tibben, M. M.
    Keessen, M.
    Rehorst, H.
    Beijnen, J. H.
    Schellens, J. H. M.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (06) : 1197 - 1205
12345